The estimated Net Worth of Douglas B. Snyder is at least $3.81 millió dollars as of 6 April 2021. Mr. Snyder owns over 8,400 units of GW Pharmaceuticals stock worth over $4,329 and over the last 6 years he sold GWPH stock worth over $919,845. In addition, he makes $2,885,930 as Chief Legal Officer at GW Pharmaceuticals.
Sign up
Mr. Snyder GWPH stock SEC Form 4 insiders trading
Douglas has made over 12 trades of the GW Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 8,400 units of GWPH stock worth $152,208 on 6 April 2021.
The largest trade he's ever made was exercising 144,420 units of GW Pharmaceuticals stock on 26 February 2021 worth over $10,109. On average, Douglas trades about 21,510 units every 45 days since 2019. As of 6 April 2021 he still owns at least 61,848 units of GW Pharmaceuticals stock.
You can see the complete history of Mr. Snyder stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Douglas Snyder biography
Douglas Snyder serves as Chief Legal Officer of the Company. Mr. Snyder brings more than 20 years of experience providing counsel in the pharmaceutical industry, at the U.S. Food and Drug Administration (“FDA”) and in private practice. Prior to joining the Company, he led the legal and compliance teams as senior vice president, general counsel, and secretary for Actelion U.S., a pharmaceuticals and biotechnology company. Prior to that, Mr. Snyder held the position of senior vice president, general counsel, secretary at Eisai Inc., a pharmaceutical subsidiary of a research-based human health care company, where he led the Legal, Compliance, Legislative Affairs, Internal Audit and Security Group. From 1999-2005, he was vice-president, associate general counsel for GlaxoSmithKline (“GSK”). During his tenure at GSK, Mr. Snyder managed the legal and communications strategies related to some of GSK’s most high-profile matters concerning the New York Attorney General, the U.S. Department of Justice and the FDA. Before joining the pharmaceutical industry, he held the role of Associate General Counsel for the FDA where he counseled the Commissioner, appeared before Congress in key initiatives, and led the initial False Claims/Kickback cases against the pharmaceutical industry.
What is the salary of Douglas Snyder?
As the Chief Legal Officer of GW Pharmaceuticals, the total compensation of Douglas Snyder at GW Pharmaceuticals is $2,885,930. There are 3 executives at GW Pharmaceuticals getting paid more, with Justin Gover having the highest compensation of $7,864,300.
How old is Douglas Snyder?
Douglas Snyder is 55, he's been the Chief Legal Officer of GW Pharmaceuticals since 2017. There are 7 older and 5 younger executives at GW Pharmaceuticals. The oldest executive at GW Pharmaceuticals is William Waldegrave, 73, who is the Non-Executive Independent Director.
What's Douglas Snyder's mailing address?
Douglas's mailing address filed with the SEC is SOVEREIGN HOUSE, VISION PARK, HISTON, , CAMBRIDGE, X0, CB24 9BZ.
Insiders trading at GW Pharmaceuticals
Over the last 6 years, insiders at GW Pharmaceuticals have traded over $60,899,192 worth of GW Pharmaceuticals stock and bought 7,200 units worth $48,960 . The most active insiders traders include Geoffrey W Dr Guy, James Noble és Justin D. Gover. On average, GW Pharmaceuticals executives and independent directors trade stock every 10 days with the average trade being worth of $8,011. The most recent stock trade was executed by Douglas B. Snyder on 6 April 2021, trading 8,400 units of GWPH stock currently worth $152,208.
What does GW Pharmaceuticals's logo look like?
Complete history of Mr. Snyder stock trades at GW Pharmaceuticals
GW Pharmaceuticals executives and stock owners
GW Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Justin Gover,
Chief Executive Officer, Executive Director -
Geoffrey Guy,
Executive Chairman of the Board -
Volker Knappertz,
Chief Medical Officer -
Douglas Snyder,
Chief Legal Officer -
Scott Giacobello,
Chief Financial Officer -
Christopher Tovey,
Chief Operating Officer -
Adam George,
Managing Director - U.K., Company Secretary -
Cabot Brown,
Non-Executive Independent Director -
James Noble,
Non-Executive Independent Director -
Catherine Mackey,
Non-Executive Independent Director -
Alicia Secor,
Non-Executive Independent Director -
William Waldegrave,
Non-Executive Independent Director -
David Gryska,
Independent Director -
Stephen Schultz,
Vice President, Investor Relations -
Darren Cline,
Chief Commercial Officer - U.S. -
Thomas G Lynch,
Director -
Julian S Gangolli,
President, North America